MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MBX Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$52.48+2.87 (+5.79%)
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$39.26 (+297.0%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.50B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.11
- Dividend yield
- –
- Free cash flow yield
- -3.40%
Fundamentals
- Net income
- -$104.32M
- EPS, diluted
- -$2.40
- Free cash flow
- -$85.20M
- Book value per share
- $8.59
- Diluted shares
- 48M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
-$117.92M
Net income
-$104.32M
EPS, diluted
-$2.40
Free cash flow
-$85.20M
Reported periodTrailing twelve months